Drug Patents owned by Actelion

1. Drug name - OPSUMIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7094781 ACTELION Sulfamides and their use as endothelin receptor antagonists
Dec, 2025

(3 years from now)

CN100432070C ACTELION Novel Sulfonamide Compounds And Their Use As Endothelin Receptor Antagonists
Dec, 2020

(1 year, 9 months ago)

CN1524079A ACTELION Novel Sulfonamide Compounds And Their Use As Endothelin Receptor Antagonists
Dec, 2020

(1 year, 9 months ago)

EP1345920A1 ACTELION Novel Sulfamides And Their Use As Endothelin Receptor Antagonists
Dec, 2026

(4 years from now)

EP1345920B1 ACTELION Novel Sulfamides And Their Use As Endothelin Receptor Antagonists
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10946015 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide Sep, 2026

(3 years from now)

US9265762 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide May, 2027

(4 years from now)

US8367685 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide Oct, 2028

(6 years from now)

US8268847 ACTELION Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor Apr, 2029

(6 years from now)

Drugs and Companies using MACITENTAN ingredient

Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherin the polysorbate represents 0.1 to 1% of the weight of said pharmaceutical composition; Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 3% of the weight of said pharmaceutical composition; Method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription

2. Drug name - TRACLEER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309126 ACTELION Dispersible bosentan tablet May, 2026

(3 years from now)

US7959945 ACTELION Dispersible bosentan tablet Dec, 2027

(5 years from now)

Drugs and Companies using BOSENTAN ingredient

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
32MG TABLET, FOR SUSPENSION;ORAL Prescription

3. Drug name - UPTRAVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7205302 ACTELION Heterocyclic compound derivatives and medicines
Oct, 2026

(4 years from now)

US8791122 ACTELION Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same
Aug, 2030

(7 years from now)

CN1516690A ACTELION Heterocyclic Derivative And Medicine
Apr, 2022

(5 months ago)

CN1301973C ACTELION Heterocyclic Derivative And Medicine
Apr, 2022

(5 months ago)

CN102459198B ACTELION Crystal
Jun, 2030

(7 years from now)

CN102459198A ACTELION Crystal
Jun, 2030

(7 years from now)

EP1400518A4 ACTELION Heterocyclic Compound Derivatives And Medicines
Apr, 2022

(5 months ago)

EP1400518B1 ACTELION Heterocyclic Compound Derivatives And Medicines
Apr, 2022

(5 months ago)

EP1400518A1 ACTELION Heterocyclic Compound Derivatives And Medicines
Apr, 2022

(5 months ago)

EP2447254A4 ACTELION Crystals
Jun, 2030

(7 years from now)

EP2447254A1 ACTELION Crystals
Jun, 2030

(7 years from now)

EP3275871A1 ACTELION Crystals
Jun, 2030

(7 years from now)

EP2447254B1 ACTELION Crystals
Jun, 2030

(7 years from now)

EP3275871B1 ACTELION Crystals
Jun, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173881 ACTELION Therapeutic compositions containing macitentan Aug, 2029

(6 years from now)

US9284280 ACTELION Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide Jun, 2030

(7 years from now)

US10828298 ACTELION Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide Dec, 2036

(14 years from now)

US10821108 ACTELION Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide Dec, 2036

(14 years from now)

Drugs and Companies using SELEXIPAG ingredient

Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan; Method of treating pulmonary arterial hypertension comprising administering a crystalline form of selexipag; Method of treating pulmonary arterial hypertension comprising administering a tablet containing selexipag; Method of treating pulmonary arterial hypertension comprising administering a solid preparation containing selexipag

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1.8MG/VIAL POWDER;INTRAVENOUS Prescription

4. Drug name - VELETRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8598227 ACTELION Epoprostenol formulation and method of making thereof Feb, 2027

(4 years from now)

US8318802 ACTELION Epoprostenol formulation and method of making thereof Mar, 2027

(4 years from now)

Drugs and Companies using EPOPROSTENOL SODIUM ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG BASE/VIAL INJECTABLE;INJECTION Prescription
EQ 1.5MG BASE/VIAL INJECTABLE;INJECTION Prescription

availability in other generic markets.

Click on the highlighted region to filter.